NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07307443 2025-12-29
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07294261 2025-12-19
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06258642 2025-08-20
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Fudan University
Phase NA Recruiting
NCT04136535 2025-07-22
PCA
Fudan University
Phase 2 Recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07037680 2025-07-09
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06977828 2025-06-29
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07022301 2025-06-15
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
Phase 2 Not yet recruiting
NCT06978153 2025-05-18
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting